Form 10-Q REXAHN PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Affirms Rexahn (RNN) at 'Buy'; Comments on Q2 Results, Pipeline Update
August 14, 2014 9:45 AM EDTRoth Capital maintains Rexahn Pharmaceuticals (AMEX: RNN) at Buy with a price target of $3 following the company's Q2 results and pipeline update.
Analyst Joseph Pantginis commented, The financial results currently do not impact our investment case. The... More
Rexahn Pharmaceuticals (RNN) Posts Breakeven Q2 Loss; Issues Pipeline Update
August 14, 2014 9:04 AM EDTRexahn Pharmaceuticals (AMEX: RNN) reported Q2 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02).
Pipeline Update:
Supinoxin (RX-5902)
In August 2013, Rexahn initiated a Phase I dose-escalation study of Supinoxin designed to evaluate the safety, tolerability, dose-limiting toxicities and maximal tolerated dose (MTD) in cancer patients with solid tumors that have previously failed treatment with approved therapies. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. In July, Rexahn announced that four dose groups (25, 50, 100 and 150 mg) had... More
